This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
31 May 2023
PONE-D-23-04467Tributyrin alleviates gut microbiota dysbiosis to repair intestinal damage in antibiotic-treated micePLOS ONE
Dear Dr. Song,
Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
Please submit your revised manuscript by Jul 15 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at gro.solp@enosolp. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
Please include the following items when submitting your revised manuscript:
A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.
We look forward to receiving your revised manuscript.
Kind regards,
Marwa Ibrahim Abd El-Hamid
Academic Editor
PLOS ONE
Journal Requirements:
When submitting your revision, we need you to address these additional requirements.
1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at
https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and
https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf
2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.
Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.
Upon resubmission, please provide the following:
a) The name of the colleague or the details of the professional service that edited your manuscript.
b) A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file).
c) A clean copy of the edited manuscript (uploaded as the new *manuscript* file).
3. Thank you for stating the following financial disclosure:
"Y.S.was supported by the National Natural Science Foundation of China (81973033)."
Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed.
Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.
4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.
Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.
Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.
We will update your Data Availability statement to reflect the information you provide in your cover letter.
5. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.
In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at gro.solp@enosolp if you have any questions.
Additional Editor Comments:
Dear authors
An English edition is needed as per the reviewer comment.
[Note: HTML markup is below. Please do not edit.]
Reviewers' comments:
Reviewer's Responses to Questions
Comments to the Author
1. Is the manuscript technically sound, and do the data support the conclusions?
The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
Reviewer #1: Yes
**********
2. Has the statistical analysis been performed appropriately and rigorously?
Reviewer #1: Yes
**********
3. Have the authors made all data underlying the findings in their manuscript fully available?
The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.
Reviewer #1: Yes
**********
4. Is the manuscript presented in an intelligible fashion and written in standard English?
PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
Reviewer #1: Yes
**********
5. Review Comments to the Author
Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
Reviewer #1: The authors established an intestinal microbiota disorder model using ceftriaxone sodium via gavage to investigate the effects of different TB doses for restoring gut microbiota and intestinal injury. It sound excellent.
1.Many careless mistakes are involved in the manuscript, eg. In Abstract, writing as ABx group or Abx group. In the manuscript, writing as SCFAs or SCFA, muc2 or MUC2; p or P; ‘. [35].’;“Studies have shown that the Muribaculaceae abundance strongly correlates with propionic acid.”this sentence needs to supported by references. Some bacteria are italic, but others not.
2.Please tell the reason for 11 days of TB interventions, the reason for using daily dose of 0.3 and 3g/kg, respectively, not for other concentrations.
3.In Methods section, how to use GC/MSD analysis to measure SCFAs needs to be described.
4.LPS level was determined by ELISA? ELISA is based on antibody and antigen response, but LPS determination based on Limulus reagent, it’s different.
5.In Methods section, primary and secondary antibodies used in Western blot needs to provide the products numbers and associated companies. And all primary antibodies are‘Rabbit polyclonal antibody’, is that true? Why not use monoclonal antibody?
6.Statistical analysis: compared by analysis of variance (ANOVA), here, not complete, should like one-way or two-ways...; why just use nonparametric test, for the mice, represents a relative consistent.
7.In figure 5, Bifidobacterium in genus level is increased with TB treatment, but normal level in NC group is too low as similar as M group, how to explain? In addition, several bacterial showed no difference, such as Alloprevotella and Parabacteroides, why the authors showed this in figure 5?
8.My another concern is the model. ceftriaxone sodium was used in this study to generate Model for gut dysbiosis, but this antibiotics is broad-spectrum anti-bacteria including anti-probiotics and anti-pathogens, the authors should provide single differential bacteria figure in Figure 5 between NC and Abx groups to help us know the specific components features of gut dysbiosis generated by ceftriaxone sodium. In figure 5, the differential bacteria analysis between NC and Abx groups needs to be shown one by one.
9.Many grammar errors needs to be corrected.
Such as: several sentences needs to be rectified: After TB intervention, these indexes were reduced compared to M mice, and the TL group was better than the TH group. Rectify this sentence.
Similarly, please rectify “After TB intervention, these indicators were reduced compared to the M group, and the TL group was better than the TH group (p < 0.05).”
‘the mice's gut digestion slows down, so they eat less and lose weight.’
10.Which inflammatory cells are responsible for the inflammation. The authors needs to detect this.
11.As we known, TB or butyrate suppress the inflammation via binding GPR receptors or inhibiting HDACs, but these molecular pathways are not presented in the manuscript.
**********
6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.
If you choose “no”, your identity will remain anonymous but your review may still be made public.
Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
Reviewer #1: No
**********
[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]
While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at gro.solp@serugif. Please note that Supporting Information files do not need this step.
If you have any questions on tributyrin benefits. We will give the professional answers to your questions.